OOIR: Observatory of International Research

Papers

(The TQCC of JCO Precision Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block	86
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine	81
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy	66
Incidental Diffuse Midline Glioma, H3 K27-Altered of the Pons Without Significant Coalterations	62
Identification and Validation of Gastric Adenocarcinoma Prognosis Features Based on Neutrophil-Related Genes	56
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer	56
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab	55
Role of Novel Bispecific Antibodies and Immunotherapy in Non–Small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations	55
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma	54
Anti-Epidermal Growth Factor Receptor Therapy in EGFR -Amplified Esophagogastric Cancers: An Underestimated Efficacy	54
Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer	48
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome	45
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer	44
Parent Quality of Life After Disclosure of Pediatric Oncology Germline Sequencing Results	43
Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma	42
Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study	39
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers	38
Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma	37
Erratum: Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States	37
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network	34
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types	33
Personalized Molecular Monitoring of a Cryptic DIAPH1::PDGFRB Fusion in Chronic Eosinophilic Leukemia Using Droplet Digital Polymerase Chain Reaction	32
Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma	31
Clonal Evolution of Endometriosis to Peritoneal Endometrioid Carcinoma via PTEN Biallelic Inactivation: A Case Report With Integrated Genomic and Patholo	31
Prognostic Role of MTAP Loss in Cholangiocarcinoma	30

Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Explora	28
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B	27
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care	27
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms	27
Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer	26
Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer	25
Acknowledgment of Reviewers, 2025	25
Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted Therapies	24
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification	24
Reply to: Beyond the Score: Integrating Hypoxia Signatures Into Risk-Adapted Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer	23
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia	23
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors	23
Fatal Intracranial Hemorrhage With Belzutifan in von Hippel-Lindau Disease–Associated Hemangioblastoma: A Case Report	23
Anti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer: A Case Report	23
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies	22
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer	22
Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis	22
Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model	22
Asynchronous Contralateral Primaries of Small Cell Carcinoma of the Ovary, Hypercalcemic Type in Germline SMARCA4 Pathogenic Variant Carriers	21
Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway	21
Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial	21
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma	21
Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2–Low Tumors in BRCA1/2 -Mutated Triple-Negative Breast Cancer	21
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma	21
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positi	21
Prognostic Significance of Tumor-Infiltrating Lymphocytes Determined Using LinkNet on Colorectal Cancer Pathology Images	20
Effect of MYCN Amplification on Tumor Response and Recurrence in Patients With Stage IV Neuroblastoma	20
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for T	20
DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers	20
Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape	20
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review	20
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Bre	19
Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection	19
Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors	18
Evaluating Patterns ofSDHxTumor Presentation by Gene and Variant Type: A Retrospective Analysis of a Large Clinical Cohort	18
Erratum: Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma	18
Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors	18
Identification of Targetable EGFR Mutations in Ovarian Cancer	18
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients	18
PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis	18
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma	18
Assessment of Circulating Tumor DNA Burden in Patients With Metastatic Gastric Cancer Using Real-World Data	17
Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors	17
Unraveling Dexamethasone-Induced Neurobehavioral and Sleep Problems in Children With ALL: Which Determinants Are Important?	17
Unveiling the Origins of Pathogenic TP53 Variants in Clinical Context: A Molecular Tumor Board Case Discussion	17
Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes	17
Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing	17
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study	17
Intracranial Activity of Selpercatinib in Chinese Patients With AdvancedRETFusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial	17
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma	16

Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2–Low Stag	16
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study	16
EWSR1-PATZ1 Fusion Gene in Ependymoma: A Report of Two Adult Cases and Systematic Review of Literature	16
Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium	16
Prognostic Significance of Isolated Tumor Cells and the Role of Immunohistochemistry in Nodal Evaluation in Breast Cancer: A SEER-Based Analysis and Reappraisal	16
Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer	16
Phase II Study of Vismodegib in Patients With SMO- or PTCH1 -Mutated Tumors: Results From the National Can	16
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network	16
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma	16
Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer	15
Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma	15
Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey	15
Computational Advancements in Cancer Combination Therapy Prediction	15
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial	15
Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer	15
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions	15
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma	15
Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes	14
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes	14
Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents	14
Combination Therapy With Olaparib Plus Lenvatinib in a Patient With BRCA2 -Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report	14
Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant	14
Liposarcoma and Leiomyosarcoma as the First Manifestation of Familial Retinoblastoma: Implications for Genetic Testing and Carrier Surveillance	14
Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab	14
Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort	13
Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele	13
Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas	13
Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non–Small-Cell Lung Cancer	13
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer	13
Immunotherapy in Synchronous Gastric and Colonic Deficient Mismatch Repair Malignancies in a Case Series of Patients With Lynch Syndrome	13
Erratum: Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay	13
Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape	13
Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets	13
Swiss-PO 2025: Advancing Cancer Mutation and Structural Analysis for Precision Oncology With the Latest Release	13
Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database	13
Erratum: Association of Baseline Tumor-Specific Neoantigens and CD8 ⁺ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Chec	13
5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma	13
Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study	12
Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability	12
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?	12
Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval	12
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis	12
Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Uti	12
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study	12
Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue	12
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E	12
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations	12
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing	12
NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor	12
Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment	12
Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma	12
Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor	12
Erratum: Reply to S. Di Cosimo et al	11
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival	11
Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial	11
Vabametkib Treatment in Refractory Glioblastoma: A Case Report	11
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer	11
Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia	11
Urban-Rural and Socioeconomic Differences in Patient Knowledge and Perceptions of Genomic Tumor Testing	11
Reply to S. Di Cosimo et al	11
CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance M	11
Role of Circulating Tumor DNA Tumor Fraction in Advanced Non–Small Cell Lung Cancer and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study	11
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer	11
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study	10
Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer	10
Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance	10
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized T	10
Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil	10
Remission of TP53 -Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD3	10
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose D	10
Imaging- and Tumor Biomarker–Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer	10
Olaparib Response in a Patient With Platinum-Refractory Germ Cell Tumor Harboring a Somatic BRIP1 Mutation	10
Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study	10
Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non–Small Cell Lung Cancer: An Updated Meta-Analysis	10
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases	10
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2	10
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations	10
PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma	10
Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase–Fused Pediatric High-Grade CNS Tumors	10
Toward Equitable Precision Oncology: Monitoring Racial and Ethnic Inclusion in Genomics and Clinical Trials	10

Increased Selfness in the Tumor Emerges as a Possible Immune Sculpting Mechanism	10
RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer	10
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma	10
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer	10
Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?	9
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	9
Chemotherapy-Induced Peripheral Neuropathy and Falls in Cancer Survivors Relate to Digital Balance and Gait Impairments	9
Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer	9
Elucidating Metastatic Organotropism in Renal Cell Carcinoma	9
Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board	9
Precision Medicine Program in Chinese Pediatric Patients With Sarcoma	9
Erratum	9
Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer	9
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations	9
Incidental Adrenal Lesions in Familial Adenomatous Polyposis	9
Case of KRAS G12C-Mutated AML Treated With Sotorasib	9
Response to MEK Inhibitor Therapy inMAP2K1(MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape ofMAP2K1Mutations in Non–Small-Cell Lung Cancer	9
Erratum: Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma	9
Optimizing Mainstreaming of Genetic Testing in Parallel With Ovarian and Endometrial Cancer Tumor Testing: How Do We Maximize Our Impact?	9
Clinical Utility of a Circulating Tumor Cell–Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non–Small Cell Lung Cancer	9
Integrated Genetic Information of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Traits Improves Hepatocellular Carcinoma Risk Stratification and Screening	9
Impact of Multicancer Screening on Late-Stage Cancer at Diagnosis in Breast Cancer Survivors: A Modeling Study	9
Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis	9
Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort	9
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression	9
Erratum: Pharmacodynamic Activity of [ ¹⁸ F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA	9
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer	8
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy	8
MIR145 Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome	8
Clinical Response to Poly(ADP-ribose) Polymerase Inhibitor in Metastatic Breast Cancer With a Germline Reduced-Penetrance BRCA2 Pathogenic Variant: A Molecular Tumor Board Discussion	8
Abscopal Effect of Radiation on Liver Metastases of Poorly Differentiated Parotid Carcinoma	8
Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma	8
Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing	8
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial	8
ALK -Rearranged Non–Small Cell Lung Cancer Presenting as a Large Mediastinal Mass: A Case Report	8
Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib	8
Therapeutic Outcomes and Biomarker Potential of CDKL3 of Neoadjuvant Chemotherapy in Patients With Stage IIIC Versus Stage IV Epithelial Ovarian Cancer	8
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	8
Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer	8
Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review	8
Complete Response to Immune Checkpoint Inhibitor–Based Combination Therapy in PD-L1–High, Tumor Mutational Burden–Low Ovarian Sarcomatoid Squamous Cell Carcinoma	8
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance	8
Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers	8
Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an	8
Molecular and Clinical Profile of a RET-Rearranged Colorectal Cancer With Prolonged Response to Platinum Therapy and Subsequent Targeted Treatment With Selpercatinib	8
Clinical Trial Diversity: A Bend in the Arc Toward Justice	8
Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications	8
Utility of Tumor-Informed Circulating Tumor DNA for Monitoring Treatment Response in Nonmetastatic, Locally Advanced Penile and Primary Urethral Cancers	8
Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma	8
Reply to: “On the Distinction Between Prognostic and Predictive Inference in Multicancer Early Detection” and “Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Cauti	8
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 ⁺ and PD-1 ⁺ Cells Predict Superior Patien	8
Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review	8
Microsatellite Peak Shifts in Polymerase Chain Reaction-Based Fragment Length Data Correlate With Microsatellite Instability Degree and Vary With Mismatch Repair Gene Defects and Tumor Size	8
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study	8
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols	8
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer	8
Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review	8
Erratum: Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lun	8
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer	7
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care	7
Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations	7
Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized	7
Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2 -Amplified Metastatic Colorectal Cancer	7
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics	7
Publishing Prediction Models in Precision Oncology: A Summary of Guidelines and Recommendations	7
Human Epidermal Growth Factor Receptor 2 Testing in Urothelial Carcinoma	7
Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer	7
ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases	7
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer	7
Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis	7
Age-Related Germline Landscape of Endometrial Cancer: Focus on Early-Onset Cases	7
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion	7
Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy	7
Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report	7
Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma	7
Improved Cancer-Specific Risk Stratification by the Lymph Node Ratio-Based Nomogram: A Potential Role in Guiding Postoperative Management Decisions for Oral Cavity Carcinoma	7
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT	7
Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non–Small-Cell Lung Cancer	7
Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study	7
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function	7
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis	7
Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States	7
Validation of the Transcription Association Chromosomal Instability Index Biomarker on RNA Sequencing in Soft Tissue Sarcomas	7
Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection	7
Parents' Experiences With and Preferences for Receiving Information About Tumor Genomic Sequencing: Findings From a Qualitative Study and Implications for Practice	7
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry	7
BRCA1 Methylation in Circulating Free DNA: A Constitutional Matter?	7
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival	7
Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing	7
Mutation Burden Independently Predicts Survival in the Pan-Cancer Atlas	6
Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy–Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors	6
Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022	6
Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations	6
Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma	6
Epithelial Abnormalities in the High-Risk Fallopian Tube of a Rare TP53 / BRCA2 Li-Fraumeni Syndrome Patient With Multiple Tumors	6